The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Mass spectrometry-based technologies for MRD detection in myeloma: insights into the BLOOM study
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses advancements in blood-based technologies for the diagnosis and prognostication of multiple myeloma. Dr Ramasamy highlights the BLOOM study, which uses quantitative immunoprecipitation mass spectrometry (QIP-MS)-based technology to assess measurable residual disease (MRD) negativity, and has been able to identify patients with prolonged progression-free survival and overall survival (PFS; OS). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
